Emerging technologies and their impact on regulatory science. Issue 1 (January 2022)
- Record Type:
- Journal Article
- Title:
- Emerging technologies and their impact on regulatory science. Issue 1 (January 2022)
- Main Title:
- Emerging technologies and their impact on regulatory science
- Authors:
- Anklam, Elke
Bahl, Martin Iain
Ball, Robert
Beger, Richard D
Cohen, Jonathan
Fitzpatrick, Suzanne
Girard, Philippe
Halamoda-Kenzaoui, Blanka
Hinton, Denise
Hirose, Akihiko
Hoeveler, Arnd
Honma, Masamitsu
Hugas, Marta
Ishida, Seichi
Kass, George EN
Kojima, Hajime
Krefting, Ira
Liachenko, Serguei
Liu, Yan
Masters, Shane
Marx, Uwe
McCarthy, Timothy
Mercer, Tim
Patri, Anil
Pelaez, Carmen
Pirmohamed, Munir
Platz, Stefan
Ribeiro, Alexandre JS
Rodricks, Joseph V
Rusyn, Ivan
Salek, Reza M
Schoonjans, Reinhilde
Silva, Primal
Svendsen, Clive N
Sumner, Susan
Sung, Kyung
Tagle, Danilo
Tong, Li
Tong, Weida
Eijnden-van-Raaij, Janny van den
Vary, Neil
Wang, Tao
Waterton, John
Wang, May
Wen, Hairuo
Wishart, David
Yuan, Yinyin
Slikker Jr., William
… (more) - Other Names:
- Slikker William guest-editor.
- Abstract:
- There is an evolution and increasing need for the utilization of emerging cellular, molecular and in silico technologies and novel approaches for safety assessment of food, drugs, and personal care products. Convergence of these emerging technologies is also enabling rapid advances and approaches that may impact regulatory decisions and approvals. Although the development of emerging technologies may allow rapid advances in regulatory decision making, there is concern that these new technologies have not been thoroughly evaluated to determine if they are ready for regulatory application, singularly or in combinations. The magnitude of these combined technical advances may outpace the ability to assess fit for purpose and to allow routine application of these new methods for regulatory purposes. There is a need to develop strategies to evaluate the new technologies to determine which ones are ready for regulatory use. The opportunity to apply these potentially faster, more accurate, and cost-effective approaches remains an important goal to facilitate their incorporation into regulatory use. However, without a clear strategy to evaluate emerging technologies rapidly and appropriately, the value of these efforts may go unrecognized or may take longer. It is important for the regulatory science field to keep up with the research in these technically advanced areas and to understand the science behind these new approaches. The regulatory field must understand the criticalThere is an evolution and increasing need for the utilization of emerging cellular, molecular and in silico technologies and novel approaches for safety assessment of food, drugs, and personal care products. Convergence of these emerging technologies is also enabling rapid advances and approaches that may impact regulatory decisions and approvals. Although the development of emerging technologies may allow rapid advances in regulatory decision making, there is concern that these new technologies have not been thoroughly evaluated to determine if they are ready for regulatory application, singularly or in combinations. The magnitude of these combined technical advances may outpace the ability to assess fit for purpose and to allow routine application of these new methods for regulatory purposes. There is a need to develop strategies to evaluate the new technologies to determine which ones are ready for regulatory use. The opportunity to apply these potentially faster, more accurate, and cost-effective approaches remains an important goal to facilitate their incorporation into regulatory use. However, without a clear strategy to evaluate emerging technologies rapidly and appropriately, the value of these efforts may go unrecognized or may take longer. It is important for the regulatory science field to keep up with the research in these technically advanced areas and to understand the science behind these new approaches. The regulatory field must understand the critical quality attributes of these novel approaches and learn from each other's experience so that workforces can be trained to prepare for emerging global regulatory challenges. Moreover, it is essential that the regulatory community must work with the technology developers to harness collective capabilities towards developing a strategy for evaluation of these new and novel assessment tools. … (more)
- Is Part Of:
- Experimental biology and medicine. Volume 247:Issue 1(2022)
- Journal:
- Experimental biology and medicine
- Issue:
- Volume 247:Issue 1(2022)
- Issue Display:
- Volume 247, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 247
- Issue:
- 1
- Issue Sort Value:
- 2022-0247-0001-0000
- Page Start:
- 1
- Page End:
- 75
- Publication Date:
- 2022-01
- Subjects:
- Emerging technologies -- biomarkers -- regulatory science -- risk assessment -- bioimaging -- bioinformatics
Physiology -- Periodicals
Biology, Experimental -- Periodicals
Medicine, Experimental -- Periodicals
610.72 - Journal URLs:
- http://ebm.rsmjournals.com/ ↗
http://ebm.sagepub.com/ ↗
http://www.ebmonline.org ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/15353702211052280 ↗
- Languages:
- English
- ISSNs:
- 1535-3702
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18370.xml